Transcriptomic and Gene Expression Analysis (RNA-Seq)

The contract calls for the performance of RNA sequencing to assess transcriptional changes in organoids after prolonged exposure to pharmaceutical agents, with a focus on identifying differential gene expression patterns, conducting comprehensive pathway analysis, and delivering interpreted results that link molecular responses to drug effects. The work requires technical expertise in next-generation sequencing, bioinformatics, and biological data analysis to generate actionable insights from complex transcriptomic datasets derived from organoid models. The solicitation is issued as a subcontract under the U.S. Department of Health and Human Services, specifically by the FDA Office of Acquisition and Grant Services, and is classified under NAICS code 541715 for Research and Development in the Physical, Engineering, and Life Sciences. The opportunity was posted on June 22, 2026, with a strict response deadline of July 6, 2026, at 5:00 PM. The place of performance and point of contact details are not specified, and no set-aside provisions apply. Bidders must be prepared to meet rigorous analytical standards and deliver scientifically valid interpretations aligned with regulatory research objectives.